Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11

Katrina Sleeman; Tiffany G Sheu; Zack Moore; Susan Kilpatrick; Shikha Garg; Alicia M Fry; Larisa V Gubareva

doi:10.3201/eid1711.110787

Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11

Emerg Infect Dis. 2011 Nov;17(11):2043-6. doi: 10.3201/eid1711.110787.

Authors

Katrina Sleeman¹, Tiffany G Sheu, Zack Moore, Susan Kilpatrick, Shikha Garg, Alicia M Fry, Larisa V Gubareva

Affiliation

¹ Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.

Abstract

Oseltamivir is 1 of 2 antiviral medications available for the treatment of influenza B virus infections. We describe and characterize a cluster of influenza B viruses circulating in North Carolina with a mutation in the neuraminidase active site that may reduce susceptibility to oseltamivir and the investigational drug peramivir but not to zanamivir.

MeSH terms

Acids, Carbocyclic
Adolescent
Adult
Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use
Catalytic Domain / genetics
Child
Child, Preschool
Cyclopentanes / pharmacology
Cyclopentanes / therapeutic use
Drug Resistance, Viral / genetics
Guanidines / pharmacology
Guanidines / therapeutic use
Hemagglutinin Glycoproteins, Influenza Virus / genetics
Humans
Infant
Influenza B virus / classification
Influenza B virus / drug effects
Influenza B virus / genetics*
Influenza, Human / drug therapy
Influenza, Human / epidemiology
Microbial Sensitivity Tests
Middle Aged
Mutation*
Neuraminidase / genetics*
North Carolina / epidemiology
Oseltamivir / pharmacology
Oseltamivir / therapeutic use
Phylogeny
Polymorphism, Single Nucleotide
Young Adult

Substances

Acids, Carbocyclic
Antiviral Agents
Cyclopentanes
Guanidines
Hemagglutinin Glycoproteins, Influenza Virus
Oseltamivir
Neuraminidase
peramivir